Cargando…

IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production

BACKGROUND: Autoimmune hemolytic anemia (AIHA), a life-threatening anemia with rapid onset, is caused by autoantibody directed to self red blood cells (RBCs). Currently, mechanisms underlying AIHA pathogenesis are largely undefined. Here we explored the correlation of IL-33 with AIHA disease activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Xiangmao, Zhang, Tenglong, Wang, Chunhong, Ren, Tao, Wen, Zhenke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681137/
https://www.ncbi.nlm.nih.gov/pubmed/26675669
http://dx.doi.org/10.1186/s12967-015-0745-0
_version_ 1782405706093166592
author Bu, Xiangmao
Zhang, Tenglong
Wang, Chunhong
Ren, Tao
Wen, Zhenke
author_facet Bu, Xiangmao
Zhang, Tenglong
Wang, Chunhong
Ren, Tao
Wen, Zhenke
author_sort Bu, Xiangmao
collection PubMed
description BACKGROUND: Autoimmune hemolytic anemia (AIHA), a life-threatening anemia with rapid onset, is caused by autoantibody directed to self red blood cells (RBCs). Currently, mechanisms underlying AIHA pathogenesis are largely undefined. Here we explored the correlation of IL-33 with AIHA disease activity and evaluated IL-33 based therapeutics in AIHA treatment. METHODS: Thirty patients diagnosed with AIHA of warm-type autoantibodies without treatment were enrolled and followed up for 6 months. Levels of cytokines including IL-33, IL-4, IL-6 and IL-13 was determined with ELISA. AIHA disease activity was presented by levels of reticulocyte count, hemoglobin and lactate dehydrogenase. Serum RBC-bound IgG autoantibody was detected using anti-IgG antibody with flow cytometry. To evaluate the effect of IL-33 blockade on AIHA development, groups of B6 mice were immunized with rat RBCs plus recombinant IL-33 protein or IL-33 neutralizing antibody respectively and detected for levels of anti-RBC antibody, frequency of reticulocytes and destruction of transfused syngeneic mouse RBCs. RESULTS: Serum level of IL-33 was higher in AIHA patients compared with healthy individuals. Of interest, serum IL-33 was positively correlated with AIHA disease activity and sensitive to their changes in AIHA patients under clinical management. Mechanistically, IL-33 could promote the production of anti-RBC autoantibody. Serum IL-33 was closely associated with serum anti-RBC autoantibody and sensitive to their changes in AIHA patients. Accordingly, blockade of IL-33 interfered with AIHA incidence and ameliorated disease activity. Vice vasa, enforced IL-33 promoted AIHA incidence and disease activity. CONCLUSIONS: IL-33 was a potential biomarker for monitoring disease activity and therapeutic response in AIHA patients. Targeting IL-33 was a promising strategy for controlling autoantibody production in AIHA patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0745-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4681137
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46811372015-12-17 IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production Bu, Xiangmao Zhang, Tenglong Wang, Chunhong Ren, Tao Wen, Zhenke J Transl Med Research BACKGROUND: Autoimmune hemolytic anemia (AIHA), a life-threatening anemia with rapid onset, is caused by autoantibody directed to self red blood cells (RBCs). Currently, mechanisms underlying AIHA pathogenesis are largely undefined. Here we explored the correlation of IL-33 with AIHA disease activity and evaluated IL-33 based therapeutics in AIHA treatment. METHODS: Thirty patients diagnosed with AIHA of warm-type autoantibodies without treatment were enrolled and followed up for 6 months. Levels of cytokines including IL-33, IL-4, IL-6 and IL-13 was determined with ELISA. AIHA disease activity was presented by levels of reticulocyte count, hemoglobin and lactate dehydrogenase. Serum RBC-bound IgG autoantibody was detected using anti-IgG antibody with flow cytometry. To evaluate the effect of IL-33 blockade on AIHA development, groups of B6 mice were immunized with rat RBCs plus recombinant IL-33 protein or IL-33 neutralizing antibody respectively and detected for levels of anti-RBC antibody, frequency of reticulocytes and destruction of transfused syngeneic mouse RBCs. RESULTS: Serum level of IL-33 was higher in AIHA patients compared with healthy individuals. Of interest, serum IL-33 was positively correlated with AIHA disease activity and sensitive to their changes in AIHA patients under clinical management. Mechanistically, IL-33 could promote the production of anti-RBC autoantibody. Serum IL-33 was closely associated with serum anti-RBC autoantibody and sensitive to their changes in AIHA patients. Accordingly, blockade of IL-33 interfered with AIHA incidence and ameliorated disease activity. Vice vasa, enforced IL-33 promoted AIHA incidence and disease activity. CONCLUSIONS: IL-33 was a potential biomarker for monitoring disease activity and therapeutic response in AIHA patients. Targeting IL-33 was a promising strategy for controlling autoantibody production in AIHA patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0745-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-16 /pmc/articles/PMC4681137/ /pubmed/26675669 http://dx.doi.org/10.1186/s12967-015-0745-0 Text en © Bu et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bu, Xiangmao
Zhang, Tenglong
Wang, Chunhong
Ren, Tao
Wen, Zhenke
IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
title IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
title_full IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
title_fullStr IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
title_full_unstemmed IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
title_short IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
title_sort il-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681137/
https://www.ncbi.nlm.nih.gov/pubmed/26675669
http://dx.doi.org/10.1186/s12967-015-0745-0
work_keys_str_mv AT buxiangmao il33reflectsdynamicsofdiseaseactivityinpatientswithautoimmunehemolyticanemiabyregulatingautoantibodyproduction
AT zhangtenglong il33reflectsdynamicsofdiseaseactivityinpatientswithautoimmunehemolyticanemiabyregulatingautoantibodyproduction
AT wangchunhong il33reflectsdynamicsofdiseaseactivityinpatientswithautoimmunehemolyticanemiabyregulatingautoantibodyproduction
AT rentao il33reflectsdynamicsofdiseaseactivityinpatientswithautoimmunehemolyticanemiabyregulatingautoantibodyproduction
AT wenzhenke il33reflectsdynamicsofdiseaseactivityinpatientswithautoimmunehemolyticanemiabyregulatingautoantibodyproduction